In people with CF and dysglycaemia, sitagliptin intervention seems to enhance meal-related incretin responses with improved early insulin secretion and glucagon suppression without affecting postprandial glycaemia or glycated haemoglobin levels [42,43,44]. The gene discussed is INS; the disease is cystic fibrosis.